Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Avidity Biosciences Inc before investing.
In this article, we go over a few key elements for understanding Avidity Biosciences Inc’s stock price such as:
- Avidity Biosciences Inc’s current stock price and volume
- Why Avidity Biosciences Inc’s stock price changed recently
- Upgrades and downgrades for RNA from analysts
- RNA’s stock price momentum as measured by its relative strength
About Avidity Biosciences Inc
(RNA)
Before we jump into Avidity Biosciences Inc’s stock price, history, target price and what caused it to recently rise, let’s take a look at some background.
Avidity Biosciences, Inc. is a biopharmaceutical company. The Company is engaged in delivering a new class of ribonucleic acid
(RNA) therapeutics called antibody oligonucleotide conjugates (AOCs.). The Company's AOC platform is designed to combine the specificity of monoclonal antibodies (mAbs), with the precision of RNA therapeutics to target the root cause of diseases previously untreatable with RNA therapeutics. The AOC platform also has the option to deploy various types of oligonucleotides, including small interfering RNA (siRNAs) and patient measure of safety (PMOs), whose specific mechanisms of action modify RNA function in different ways. The Company's pipeline includes AOC 1001, and AOC 1020. AOC 1001 is designed to treat people with myotonic dystrophy type 1 (DM1). AOC 1020 is designed to treat people living with facioscapulohumeral.
Want to learn more about Avidity Biosciences Inc’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Avidity Biosciences Inc.
Avidity Biosciences Inc’s Stock Price as of Market Close
As of March 08, 2024, 4:00 PM, CST, Avidity Biosciences Inc’s stock price was $21.46.
Avidity Biosciences Inc is up 7.19% from its previous closing price of $20.02.
During the last market session, Avidity Biosciences Inc’s stock traded between $19.24 and $20.73. Currently, there are 76.09 million shares of Avidity Biosciences Inc stock available for purchase.
Unfortunately, Avidity Biosciences Inc’s P/E ratio is not significant enough to use for stock price evaluation. We recommend investors evaluate other financial metrics to understand its overall valuation.
Avidity Biosciences Inc Stock Price History
Avidity Biosciences Inc’s
(RNA) price is currently up 17.27% so far this month.
During the month of March, Avidity Biosciences Inc’s stock price has reached a high of $21.55 and a low of $16.30.
Over the last year, Avidity Biosciences Inc has hit prices as high as $22.82 and as low as $4.83. Year to date, Avidity Biosciences Inc’s stock is down 3.29%.
Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions
What Caused Avidity Biosciences Inc Stock’s Price to Rise?
Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?
When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of March 07, 2024, there was 1 analyst who downgraded Avidity Biosciences Inc’s stock and 3 analysts who upgraded over the last month.
Additionally, you'll want to evaluate Avidity Biosciences Inc’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Avidity Biosciences Inc’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.
Avidity Biosciences Inc’s current valuation based on AAII’s Value Grade is a F, which means it is considered to be Ultra Expensive.
Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.
Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Avidity Biosciences Inc
(RNA) by visiting AAII Stock Evaluator.
Relative Price Strength of Avidity Biosciences Inc
Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.
For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.
As of March 07, 2024, Avidity Biosciences Inc has a weighted four-quarter relative price strength of 32.72%, which translates to a Momentum Score of 96 and is considered to be Very Strong.
Want to learn more about how Avidity Biosciences Inc is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.
Avidity Biosciences Inc Stock Price: Bottom Line
As of March 8, 2024, Avidity Biosciences Inc’s stock price is $21.46, which is up 7.19% from its previous closing price.
AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Avidity Biosciences Inc stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.
Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.
Included With AAII Platinum
Screen: 23.7%
Annual Gain Since Inception. Data as of 12/31/2024.
769.3% Stock Superstars Portfolio Total Return Since Inception
U.S. Index ETF (IYY)
SSR Group 3 O'Shaughnessy portfolio has a 411.2% gain since inception performance compared to IYY at only 119.1%% Performance as of 11/29/24.
FREE REPORT
BECOME A MEMBER FOR ONLY $2
Get access to powerful investment discovery tools and a wealth of investment education to help you achieve your financial goals.